EV and pharma shakeups collide: China–Turkey fallout, US EV pressure, and Merck’s Keytruda hedge

Merck’s CEO said the company has built a “new pipeline” specifically designed to offset the eventual patent expiration of Keytruda, signaling that the firm is actively managing a future revenue cliff rather than waiting for it to arrive. The statement frames pipeline development as a hedge against loss of exclusivity, implying that Merck is prioritizing late-stage assets and lifecycle strategy to protect cash flow. In parallel, a separate report highlights that China–Turkey relations have become strained after a flagship $1 billion Chinese EV investment collapsed, threatening to slow one of Beijing’s most important economic relationships in the region. The investment fallout suggests that EV industrial policy and cross-border capital commitments are now more fragile, with political and commercial expectations colliding. Strategically, the cluster points to a broader realignment in how governments and firms manage strategic sectors—EVs and high-value biopharma—under intensifying competition and regulatory scrutiny. For China, the Turkey investment collapse risks weakening leverage tied to trade, investment, and access to European markets, potentially pushing Beijing toward alternative partners or more state-backed industrial deals. For the United States, Lucid’s CEO warning that the US cannot “stay isolated” from Chinese EV competition underscores that market share battles are increasingly treated as national competitiveness issues, not just consumer choice. The likely winners are firms with credible cost-down roadmaps and protected IP pipelines, while the losers are lagging manufacturers and investors exposed to policy-driven demand swings. Market and economic implications are likely to show up in EV supply chains, risk premia for cross-border industrial projects, and equity sentiment around growth and margin durability. Lucid’s announced $1.4bn cost-cutting program, combined with expectations of an industry “shakeout,” points to downward pressure on unprofitable capacity and higher volatility in EV-related equities and suppliers, especially those dependent on external funding. The China–Turkey investment rupture can also affect regional industrial procurement and may raise insurance and financing costs for future Turkish-linked manufacturing ventures. On the pharma side, Merck’s Keytruda patent-expiration hedge can support investor confidence in long-duration earnings, but it also keeps attention on pipeline execution risk and future launch timing—factors that can move large-cap biotech and healthcare indices. What to watch next is whether the EV “shakeout” narrative translates into concrete consolidation, further layoffs, or accelerated price competition across major markets. For China and Turkey, the trigger points are clarification of whether the collapsed $1 billion investment is being restructured, replaced, or written off, and whether government-to-government messaging restores confidence. For the US, watch for additional cost programs, production guidance revisions, and any policy signals that could reshape tariffs, subsidies, or procurement rules in response to Chinese EV scale. For Merck, the key indicators are pipeline readouts, regulatory milestones, and any changes in guidance around the timing of Keytruda’s exclusivity erosion—each of which can shift valuation assumptions quickly as the patent clock moves forward.

Geopolitical Implications

• 01

  EV industrial policy is becoming a geopolitical instrument: investment failures can quickly translate into diplomatic friction and reduced market-access leverage.

• 02

  US corporate messaging treats Chinese EV competition as a competitiveness threat, increasing the likelihood of policy interventions (tariffs, subsidies, procurement rules).

• 03

  Biopharma IP transition planning (Keytruda pipeline hedge) is a strategic economic issue, influencing investor confidence and national healthcare-industrial resilience.

Key Signals

• —Any official clarification from China and Turkey on the fate of the collapsed $1B EV investment (restructuring vs. cancellation).
• —Further announcements from US EV firms on cost programs, production guidance, and consolidation plans.
• —Merck pipeline milestone timing and regulatory updates that affect assumptions about the Keytruda exclusivity cliff.